Vivos Therapeutics, Inc. (NASDAQ: VVOS) reported Q2 EPS of ($0.18), $0.01 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $3.4 million versus the consensus estimate of $4.42 million.

For earnings history and earnings-related data on Vivos Therapeutics, Inc. (VVOS) click here.